CalAmp Earns Caterpillar Supplier Excellence Certification for Second Consecutive Year
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 17 2025
0mins
Source: Globenewswire
- Excellence Certification Achievement: CalAmp has earned Caterpillar's Supplier Excellence Certification for the second consecutive year, indicating its adherence to the highest industry standards in quality, delivery, and service, thereby solidifying its leading position in the global supply chain.
- Significantly Reduced Defect Rate: Over the past 12 months, CalAmp achieved a defect rate of 51 defects per million parts, approximately 0.005%, reflecting the company's stringent focus on precision and consistency in its global manufacturing processes, which enhances customer trust.
- Automotive-Grade Manufacturing System: CalAmp has implemented an Automotive Quality Management System aligned with IATF 16949 principles, ensuring that each device meets the rigorous design and manufacturing requirements expected of mission-critical automotive components, thereby boosting its competitiveness in the industrial and automotive OEM markets.
- Commitment to Future Connected Equipment: As OEMs advance their connected equipment strategies, CalAmp remains focused on delivering reliable telematics solutions, supporting manufacturers across construction and agriculture, ensuring device reliability to meet future market demands.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CAMP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CAMP
Wall Street analysts forecast CAMP stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.140
Low
8.00
Averages
15.25
High
18.00
Current: 4.140
Low
8.00
Averages
15.25
High
18.00
About CAMP
CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Major Wall Street Rating Changes Overview
- UBS Upgrade: UBS upgrades Dynatrace from neutral to buy, citing strong core application performance monitoring demand which is expected to drive modest growth, reflecting a healthy demand backdrop in the market.
- Bank of America Upgrade: Bank of America upgrades Kilroy Realty from neutral to buy, raising the price target from $42 to $44, indicating confidence in improving demand dynamics that are likely to enhance the company's competitive position in the REIT sector.
- DA Davidson Initiation: DA Davidson initiates coverage on Lincoln Electric with a buy rating and a $320 price target, emphasizing its potential as an industrial compounder, which suggests future growth opportunities in the sector.
- Goldman Sachs Neutral Reiteration: Goldman Sachs reiterates Tesla as neutral, forecasting that its Q2 2026 delivery numbers will exceed consensus expectations, thereby boosting confidence in the company's future performance.
See More
Camp4 Therapeutics Q1 Earnings Report Analysis
- Earnings Miss: Camp4 Therapeutics reported a Q1 GAAP EPS of -$0.32, missing expectations by $0.11, indicating challenges in profitability that could affect investor confidence.
- Cash Position: As of March 31, 2026, the company had cash and cash equivalents of $99.2 million, down from $109.5 million as of December 31, 2025, reflecting urgent funding needs that may limit future investments.
- Sufficient Funding: Camp4 believes its current cash reserves will be adequate to fund planned activities into 2028, suggesting short-term operational sustainability, though long-term growth may require additional funding.
- Clinical Trial Progress: As CMP-002 moves toward human trials, the company's cash flow situation will directly impact its R&D capabilities and market competitiveness, making subsequent developments critical for investors.
See More
CAMP4 Therapeutics Reports Q1 2026 Financial Results and Business Highlights
- Financial Performance: CAMP4 reported a net loss of $18.33 million in Q1 2026, translating to a loss of $0.32 per share, which is an improvement from the $12.43 million loss and $0.62 per share in the same period of 2025, indicating a need for ongoing financial scrutiny despite reduced losses.
- Stable R&D Spending: The company maintained R&D expenses at $10.16 million for the quarter, nearly unchanged from $10.15 million last year, reflecting its commitment to advancing RNA-targeted therapies despite financial challenges.
- Clinical Trial Progress: CAMP4 submitted a regulatory filing in Australia to initiate a Phase 1/2 clinical trial for CMP-002 in the second half of 2026, which targets SYNGAP1-related disorders and has received orphan drug designation from the EMA, highlighting its potential market significance.
- Collaboration and Research: The company has partnered with CURE SYNGAP for the ProMMis study to explore the natural history of SYNGAP1-related disorders and develop effective therapies, while also submitting a preprint of a pioneering study aimed at creating the largest catalog of regRNAs, advancing scientific research efforts.
See More
Camp4 Therapeutics Reports FY Earnings Miss with Strong Revenue Growth
- Earnings Report: Camp4 Therapeutics reported a FY GAAP EPS of -$2.65, missing estimates by $0.77, indicating challenges in profitability that may affect investor confidence moving forward.
- Revenue Surge: The company achieved FY revenue of $3.5M, reflecting a remarkable 438.5% year-over-year increase, which, despite the lack of profitability, suggests a rising market demand for its products or services, potentially laying the groundwork for future profitability.
- Cash Position: As of December 31, 2025, Camp4's cash and cash equivalents stood at $109.5 million, up from $64.0 million in 2024, demonstrating improved financial management that supports future operational and R&D activities.
- Funding Outlook: Camp4 believes its current cash reserves will be sufficient to fund planned activities into 2028, indicating a level of confidence in financial stability and strategic planning for the coming years.
See More
CAMP4 Therapeutics Grants 8,000 Stock Options at $5.78 to New Employee
- Stock Option Grant: On January 15, 2026, CAMP4 Therapeutics granted 8,000 non-qualified stock options to a new employee at an exercise price of $5.78 per share, aimed at attracting talent and enhancing employee loyalty.
- Option Structure: The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting in monthly installments, ensuring continued employee contribution during their tenure.
- Market Compliance: This grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to attracting and retaining key talent while enhancing investor confidence through transparency and compliance.
- Strategic Implications: CAMP4 focuses on developing RNA-targeting therapeutics for genetic diseases, aiming to restore healthy protein levels in over 1,200 related disorders, showcasing its innovative potential in the biopharmaceutical sector.
See More
CAMP4 Therapeutics to Present Corporate Update at J.P. Morgan Healthcare Conference
- Conference Update: CAMP4 Therapeutics will present a corporate update at the J.P. Morgan Healthcare Conference on January 14, 2026, at 3:45 PM PST in San Francisco, showcasing its latest advancements in treating genetic diseases, which is expected to attract investor interest.
- Live Webcast: The event will be webcast on CAMP4's investor relations page, allowing global investors to access real-time information, with a replay available for 30 days post-conference, enhancing the company's transparency and investor confidence.
- Technological Platform: CAMP4's RAP Platform focuses on amplifying mRNA by targeting regulatory RNAs, aiming to treat over 1,200 genetic diseases characterized by haploinsufficiency and partial loss of function, demonstrating its innovative potential in the biopharmaceutical sector.
- Market Outlook: By developing therapies that target gene expression, CAMP4 not only aims to improve patient health outcomes but also positions itself to capture a share in the rapidly growing gene therapy market, driving long-term growth for the company.
See More
Major Wall Street Rating Changes Overview
- UBS Upgrade: UBS upgrades Dynatrace from neutral to buy, citing strong core application performance monitoring demand which is expected to drive modest growth, reflecting a healthy demand backdrop in the market.
- Bank of America Upgrade: Bank of America upgrades Kilroy Realty from neutral to buy, raising the price target from $42 to $44, indicating confidence in improving demand dynamics that are likely to enhance the company's competitive position in the REIT sector.
- DA Davidson Initiation: DA Davidson initiates coverage on Lincoln Electric with a buy rating and a $320 price target, emphasizing its potential as an industrial compounder, which suggests future growth opportunities in the sector.
- Goldman Sachs Neutral Reiteration: Goldman Sachs reiterates Tesla as neutral, forecasting that its Q2 2026 delivery numbers will exceed consensus expectations, thereby boosting confidence in the company's future performance.
See More
Camp4 Therapeutics Q1 Earnings Report Analysis
- Earnings Miss: Camp4 Therapeutics reported a Q1 GAAP EPS of -$0.32, missing expectations by $0.11, indicating challenges in profitability that could affect investor confidence.
- Cash Position: As of March 31, 2026, the company had cash and cash equivalents of $99.2 million, down from $109.5 million as of December 31, 2025, reflecting urgent funding needs that may limit future investments.
- Sufficient Funding: Camp4 believes its current cash reserves will be adequate to fund planned activities into 2028, suggesting short-term operational sustainability, though long-term growth may require additional funding.
- Clinical Trial Progress: As CMP-002 moves toward human trials, the company's cash flow situation will directly impact its R&D capabilities and market competitiveness, making subsequent developments critical for investors.
See More
CAMP4 Therapeutics Reports Q1 2026 Financial Results and Business Highlights
- Financial Performance: CAMP4 reported a net loss of $18.33 million in Q1 2026, translating to a loss of $0.32 per share, which is an improvement from the $12.43 million loss and $0.62 per share in the same period of 2025, indicating a need for ongoing financial scrutiny despite reduced losses.
- Stable R&D Spending: The company maintained R&D expenses at $10.16 million for the quarter, nearly unchanged from $10.15 million last year, reflecting its commitment to advancing RNA-targeted therapies despite financial challenges.
- Clinical Trial Progress: CAMP4 submitted a regulatory filing in Australia to initiate a Phase 1/2 clinical trial for CMP-002 in the second half of 2026, which targets SYNGAP1-related disorders and has received orphan drug designation from the EMA, highlighting its potential market significance.
- Collaboration and Research: The company has partnered with CURE SYNGAP for the ProMMis study to explore the natural history of SYNGAP1-related disorders and develop effective therapies, while also submitting a preprint of a pioneering study aimed at creating the largest catalog of regRNAs, advancing scientific research efforts.
See More
Camp4 Therapeutics Reports FY Earnings Miss with Strong Revenue Growth
- Earnings Report: Camp4 Therapeutics reported a FY GAAP EPS of -$2.65, missing estimates by $0.77, indicating challenges in profitability that may affect investor confidence moving forward.
- Revenue Surge: The company achieved FY revenue of $3.5M, reflecting a remarkable 438.5% year-over-year increase, which, despite the lack of profitability, suggests a rising market demand for its products or services, potentially laying the groundwork for future profitability.
- Cash Position: As of December 31, 2025, Camp4's cash and cash equivalents stood at $109.5 million, up from $64.0 million in 2024, demonstrating improved financial management that supports future operational and R&D activities.
- Funding Outlook: Camp4 believes its current cash reserves will be sufficient to fund planned activities into 2028, indicating a level of confidence in financial stability and strategic planning for the coming years.
See More
CAMP4 Therapeutics Grants 8,000 Stock Options at $5.78 to New Employee
- Stock Option Grant: On January 15, 2026, CAMP4 Therapeutics granted 8,000 non-qualified stock options to a new employee at an exercise price of $5.78 per share, aimed at attracting talent and enhancing employee loyalty.
- Option Structure: The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting in monthly installments, ensuring continued employee contribution during their tenure.
- Market Compliance: This grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to attracting and retaining key talent while enhancing investor confidence through transparency and compliance.
- Strategic Implications: CAMP4 focuses on developing RNA-targeting therapeutics for genetic diseases, aiming to restore healthy protein levels in over 1,200 related disorders, showcasing its innovative potential in the biopharmaceutical sector.
See More
CAMP4 Therapeutics to Present Corporate Update at J.P. Morgan Healthcare Conference
- Conference Update: CAMP4 Therapeutics will present a corporate update at the J.P. Morgan Healthcare Conference on January 14, 2026, at 3:45 PM PST in San Francisco, showcasing its latest advancements in treating genetic diseases, which is expected to attract investor interest.
- Live Webcast: The event will be webcast on CAMP4's investor relations page, allowing global investors to access real-time information, with a replay available for 30 days post-conference, enhancing the company's transparency and investor confidence.
- Technological Platform: CAMP4's RAP Platform focuses on amplifying mRNA by targeting regulatory RNAs, aiming to treat over 1,200 genetic diseases characterized by haploinsufficiency and partial loss of function, demonstrating its innovative potential in the biopharmaceutical sector.
- Market Outlook: By developing therapies that target gene expression, CAMP4 not only aims to improve patient health outcomes but also positions itself to capture a share in the rapidly growing gene therapy market, driving long-term growth for the company.
See More
